# Safety of Argatroban Infusion in Conduction Disturbances

> **NCT05740371** · PHASE4 · COMPLETED · sponsor: **Tanabe Pharma GmbH** · enrollment: 50 (actual)

## Conditions studied

- Stable Coronary Artery Disease (CAD)
- Unstable Angina (Troponin Negative)

## Interventions

- **DRUG:** Argatroban

## Key facts

- **NCT ID:** NCT05740371
- **Lead sponsor:** Tanabe Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2021-05-06
- **Final completion:** 2021-05-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740371, "Safety of Argatroban Infusion in Conduction Disturbances". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05740371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*